O Filleul1, E Crompot, S Saussez. 1. Faculty of Medicine and Pharmacy, Department of Anatomy and Cellular Biology, University of Mons, Pentagone 2C-Avenue du Champ de Mars, 6, B-7000, Mons, Belgium.
Abstract
PURPOSE: Bisphosphonates (BPs) are bone-remodeling inhibitors that are used to manage bone metastases and osteoporosis. Osteonecrosis of the jaw, however, can occur during treatment. This complication is poorly understood and is called "bisphosphonate-induced osteonecrosis of the jaw" (BIOJ). METHODS: We performed a PubMed-based review of all of the described cases of BIOJ from January 2003 (the year of the first description) to September 2009. Issues of clinical relevance, such as the primary diagnosis and type of treatment, were evaluated for each patient case. RESULTS: We retrieved 2,408 cases, 88% of which were associated with intravenous therapy, primarily with zoledronate. Of the total number of cases, 89% were associated with the treatment of a malignant condition, particularly multiple myeloma (43% of the cases). Of all the BIOJ cases, 67% were preceded by tooth extraction and only 35% of patients were cured. CONCLUSION: Prevention is better than treatment, and the establishment of meticulous oral hygiene and surgical procedures prior to commencing BP treatment is important for preventing BIOJ. Our review summarizes the current knowledge about this severe complication. Future studies, especially basic research studies, are needed to better understand this devastating disease.
PURPOSE:Bisphosphonates (BPs) are bone-remodeling inhibitors that are used to manage bone metastases and osteoporosis. Osteonecrosis of the jaw, however, can occur during treatment. This complication is poorly understood and is called "bisphosphonate-induced osteonecrosis of the jaw" (BIOJ). METHODS: We performed a PubMed-based review of all of the described cases of BIOJ from January 2003 (the year of the first description) to September 2009. Issues of clinical relevance, such as the primary diagnosis and type of treatment, were evaluated for each patient case. RESULTS: We retrieved 2,408 cases, 88% of which were associated with intravenous therapy, primarily with zoledronate. Of the total number of cases, 89% were associated with the treatment of a malignant condition, particularly multiple myeloma (43% of the cases). Of all the BIOJ cases, 67% were preceded by tooth extraction and only 35% of patients were cured. CONCLUSION: Prevention is better than treatment, and the establishment of meticulous oral hygiene and surgical procedures prior to commencing BP treatment is important for preventing BIOJ. Our review summarizes the current knowledge about this severe complication. Future studies, especially basic research studies, are needed to better understand this devastating disease.
Authors: Estee P Wang; Leonard B Kaban; Gordon J Strewler; Noopur Raje; Maria J Troulis Journal: J Oral Maxillofac Surg Date: 2007-07 Impact factor: 1.895
Authors: Alberto Bedogni; Stella Blandamura; Zerina Lokmic; Carla Palumbo; Mirko Ragazzo; Francesca Ferrari; Alberto Tregnaghi; Francesco Pietrogrande; Olindo Procopio; Giorgia Saia; Marzia Ferretti; Giorgio Bedogni; Luigi Chiarini; Giuseppe Ferronato; Vito Ninfo; Lucio Lo Russo; Lorenzo Lo Muzio; Pier Francesco Nocini Journal: Oral Surg Oral Med Oral Pathol Oral Radiol Endod Date: 2008-03
Authors: Robert A Kyle; Gary C Yee; Mark R Somerfield; Patrick J Flynn; Susan Halabi; Sundar Jagannath; Robert Z Orlowski; David G Roodman; Patricia Twilde; Kenneth Anderson Journal: J Clin Oncol Date: 2007-05-21 Impact factor: 44.544
Authors: Alberto Bedogni; Giorgia Saia; Giordana Bettini; Anita Tronchet; Andrea Totola; Giorgio Bedogni; Paolo Tregnago; Maria Teresa Valenti; Francesco Bertoldo; Giuseppe Ferronato; Pier Francesco Nocini; Stella Blandamura; Luca Dalle Carbonare Journal: Oncologist Date: 2012-06-20
Authors: Si-Huei Lee; Rai-Chi Chan; Shy-Shin Chang; Yin-Ling Tan; Kai-Hsiang Chang; Matthew C Lee; Huai-En Chang; Chien-Chang Lee Journal: Support Care Cancer Date: 2013-11-08 Impact factor: 3.603
Authors: Qunzhou Zhang; Ikiru Atsuta; Shiyu Liu; Chider Chen; Shihong Shi; Songtao Shi; Anh D Le Journal: Clin Cancer Res Date: 2013-04-24 Impact factor: 12.531